Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases. Radiopharmaceuticals may be given to the patient in several different ways. 例如, they may be given by mouth, given by injection, or placed into the eye or into the bladder. The global radiopharmaceuticals market is projected to rise by USD 7.5 十亿 2029, 根据最新的市场研究结果. 预计复合年增长率为 9.7 预测期内的百分比.

该报告涵盖了市场规模和增长, 分割, 区域细分, 竞争格局, trends and strategies for global radiopharmaceuticals market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

该行业报告提供了全球市场的市场估计和预测, 接下来是对产品的详细分析, production method, 应用, 最终用户, 和地区. The global market for radiopharmaceuticals can be segmented by product: diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals. 据研究, the diagnostic radiopharmaceuticals segment had the largest share in the global radiopharmaceuticals market. Radiopharmaceuticals market is further segmented by production method: nuclear reactor, cyclotron, generator. 在 2022, the nuclear reactor segment made up the largest share of revenue generated by the radiopharmaceuticals market. 根据应用, the radiopharmaceuticals market is segmented into: 心血管疾病, neurological disorders, 肿瘤学, 其他的. 在这些当中, the oncology segment was accounted for the highest revenue generator in 2022. 基于最终用户, the radiopharmaceuticals market also can be divided into: 诊断中心, 医院, 研究机构, 其他的. The hospitals segment captured the largest share of the market in 2022. Radiopharmaceuticals market by region is categorized into: 北美, 欧洲, 亚太, 事物 (中东和非洲), 拉美.

The diagnostic radiopharmaceuticals market is further segmented into SPECT radiopharmaceuticals, PET radiopharmaceuticals, 其他的. The latest analysis indicates that the SPECT radiopharmaceuticals segment occupied the largest share of this market in 2022 预计未来几年需求将达到最高. 此外, the therapeutic radiopharmaceuticals market has been categorized into beta emitters, alpha emitters, brachytherapy seeds, 其他的. 全球范围, the beta emitters segment made up the largest share of the radiopharmaceuticals market.

市场细分
副产品: diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals
By production method: nuclear reactor, cyclotron, generator
按申请: 心血管疾病, neurological disorders, 肿瘤学, 其他的
按最终用户: 诊断中心, 医院, 研究机构, 其他的
按地区: 北美, 欧洲, 亚太, 事物 (中东和非洲), 拉美

The report explores the recent developments and profiles of key vendors in the Global Radiopharmaceuticals Market, including Advanced Accelerator Applications S.A. (诺华公司), Australian Nuclear Science and Technology Organisation (ANSTO), 拜耳公司, Bracco S.p.A., 康德乐, 公司, Eckert & Ziegler Strahlen- und Medizintechnik AG, ECZACIBASI-MONROL Nuclear Products Co., Eli Lilly and Company, 通用电气医疗集团, IBA Radiopharma Solutions (Ion Beam Applications SA), IRE – IRE ELiT, Jubilant Life Sciences Ltd., Lantheus Holdings, 公司, Navidea Biopharmaceutical, 公司, Nordion, 公司, NTP Radioisotopes SOC Ltd., Siemens Healthineers AG, 除其他外. 在这份报告中, 全面分析关键参与者及其策略，以了解市场的竞争前景.
*索取免费样品以获得完整的公司列表

报告范围
• To analyze and forecast the market size of the global radiopharmaceuticals market.
• To classify and forecast the global radiopharmaceuticals market based on product, production method, 应用, 最终用户, 地区.
• To identify drivers and challenges for the global radiopharmaceuticals market.
• 检查竞争性发展，例如合并 & 收购, 协议, 合作与伙伴关系, ETC。, in the global radiopharmaceuticals market.
• To identify and analyze the profile of leading players operating in the global radiopharmaceuticals market.

为什么选择这份报告
• Gain a reliable outlook of the global radiopharmaceuticals market forecasts from 2023 到 2029 跨场景.
• 确定投资的增长领域.
• 通过公司简介和市场数据保持领先于竞争对手.
• 以 Excel 格式进行跨场景分析的市场预估.
• 三个月的战略咨询和研究支持.
• 为单用户许可证提供打印验证.